Ethical Aspects of Using CRISPR-Cas9 in Medicine in Kazakhstan and Worldwide
Askhat Myngbay 1 * ,
Arinaz Kabyl 1 * More Detail
1 Biology department, K. Zhubanov Aktobe regional University, Aktobe, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 23, Issue 1, pp. 93-96.
https://doi.org/10.23950/jcmk/17746
OPEN ACCESS
297 Views
122 Downloads
Author Contributions: Conceptualization, A. M.; writing – original draft preparation, A. K.; writing – review and editing, A. M.; supervision, A. M. All authors have read and agreed to the published version of the manuscript.Disclosures: The authors have no conflicts of interest.
Data availability statement: The corresponding author can provide the data supporting the study's conclusions upon request.
Artificial Intelligence (AI) Disclosure Statement: AI-Unassisted Work.
ABSTRACT
CRISPR-Cas9 is a new emerging genome editing tool, that gives hope as a cure to various diseases, including cancer and hereditary diseases. Although its accuracy in editing DNA is fascinating, recent breakthroughs in this field raise crucial ethical and legal issues. Usage of CRISPR-Cas9 raises concerns pertaining to safety, availability, religious and societal impact. Nowadays, some of the high-income countries have developed regulatory frameworks to address these concerns, however there is still a lack of global concrete regulations for all nations. In Kazakhstan, even though genome editing technology is used mostly in research, we are in demand of developing bioethical principles based on international practices. The regulatory framework would ensure a responsible approach in using this tool in medicine and research. In this review, we explored international ethical practices and examined the current situation in Kazakhstan in implementing genome editing technology. CRISPR-Cas9 is a new emerging genome editing tool, that gives hope as a cure to various diseases, including cancer and hereditary diseases. Although its accuracy in editing DNA is fascinating, recent breakthroughs in this field raise crucial ethical and legal issues. Usage of CRISPR-Cas9 raises concerns pertaining to safety, availability, religious and societal impact. Nowadays, some of the high-income countries have developed regulatory frameworks to address these concerns, however there is still a lack of global concrete regulations for all nations. In Kazakhstan, even though genome editing technology is used mostly in research, we are in demand of developing bioethical principles based on international practices. The regulatory framework would ensure a responsible approach in using this tool in medicine and research. In this review, we explored international ethical practices and examined the current situation in Kazakhstan in implementing genome editing technology.
REFERENCES
- Callaway E. UK scientists gain licence to edit genes in human embryos. Nature. 2016 Feb 1;530(7588):18–18. https://doi.org/10.1038/
- Lu L, Yu X, Cai Y, Sun M, Yang H. Application of CRISPR/Cas9 in Alzheimer’s Disease. Front Neurosci. 2021 Dec 21;15. https://doi.org/10.3389/fnins.2021.803894
- Refolo P, Ferracuti S, Grassi S, Raimondi C, Mercuri G, Zedda M, Aulino G, Spagnolo AG, Oliva A. Ethical issues in the use of genetic predictions of aggressive behavior in the criminal justice system: a systematic review. Front Genet. 2025 May 13;16:1599750. https://doi.org/10.3389/fgene.2025.1599750
- Shah P, Thornton I, Kopitnik NL, Hipskind JE. Informed Consent. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. http://www.ncbi.nlm.nih.gov/books/NBK430827/
- Gobeka HH, Şenol Y, Alijanli S, Doğan M, Ay İE. Informed consent research at a tertiary hospital: How impactful is competency in simpler versus standard consent forms for intravitreal injection therapy? J Clin Med Kazakhstan. 2023 Feb 27;20(1):18–23. https://doi.org/10.23950/jcmk/12897
- Rubeis G, Steger F. Risks and benefits of human germline genome editing: An ethical analysis. Asian Bioeth Rev. 2018 July 16;10(2):133–41. https://doi.org/10.1007/s41649-018-0056-x
- Gyngell C. Gene editing and the health of future generations. J R Soc Med. 2017 July;110(7):276–9. https://doi.org/10.1177/01410768177056
- Lander ES, Baylis F, Zhang F, Charpentier E, Berg P, Bourgain C, Friedrich B, Joung JK, Li J, Liu D, Naldini L, Nie JB, Qiu R, Schoene-Seifert B, Shao F, Terry S, Wei W, Winnacker EL. Adopt a moratorium on heritable genome editing. Nature. 2019 Mar;567(7747):165–8. https://doi.org/10.1038/d41586-019-00726-5
- Yüksel F. Comprehensive Exploration of CRISPR and Gene Editing Technologies: Applications, Ethical Considerations, and Future Implications in Genetic Research. Front Life Sci AI. 2024 Nov 1;8(1):69–69. https://doi.org/10.62802/3nwhcj06
- Caplan AL, Parent B, Shen M, Plunkett C. No time to waste—the ethical challenges created by CRISPR. EMBO Rep. 2015 Nov;16(11):1421–6. https://doi.org/10.15252/embr.201541337
- Pfeifer K, Frieß JL, Giese B. Insect allies—Assessment of a viral approach to plant genome editing. Integr Environ Assess Manag. 2022 Nov;18(6):1488–99. https://doi.org/10.1002/ieam.4577
- Billore P. Gene Editing In Soldiers: CRISPR And Human Chimeras. The Defence Horizon Journal. 2024. https://tdhj.org/blog/post/gene-editing-soldiers-crispr/
- Greene M, Master Z. Ethical Issues of Using CRISPR Technologies for Research on Military Enhancement. J Bioethical Inq. 2018 Sept 1;15(3):327–35. https://doi.org/10.1007/s11673-018-9865-6
- Cyranoski D. First CRISPR babies: six questions that remain. Nature. 2018 Nov 30; https://doi.org/10.1038/d41586-018-07607-3
- EXCLUSIVE: Chinese scientists are creating CRISPR babies. MIT Technology Review. https://www.technologyreview.com/2018/11/25/138962/exclusive-chinese-scientists-are-creating-crispr-babies/
- David Cyranoski. The CRISPR-baby scandal: what’s next for human gene-editing. Nature, 566, 440-442 (2019) https://doi.org/10.1038/d41586-019-00673-1
- Ruwitch J. His baby gene editing shocked ethicists. Now he’s in the lab again. NPR. 2023 June 8; https://www.npr.org/2023/06/08/1178695152/china-scientist-he-jiankui-crispr-baby-gene-editing
- Alzhanuly B, Sharipov K. Latest advancements in the development of new therapies for type 1 diabetes. Bratisl Lek Listy. 2024;125(8):484–91. https://doi.org/10.4149/BLL_2024_75
- Schaaf C, Sussel L. A Cure for Type 1 Diabetes: Are We There Yet? Diabetes Technol Ther. 2025 June;27(6):413–21. https://doi.org/10.1089/dia.2024.0498
- ON PUBLIC HEALTH AND HEALTHCARE SYSTEM - “Adilet” LIS [in russian]. https://adilet.zan.kz/eng/docs/K2000000360
- Rueda J, Segers S, Hopster J, Kudlek K, Liedo B, Marchiori S, Danaher J. Anticipatory gaps challenge the public governance of heritable human genome editing. J Med Ethics;51(5):e109801. https://doi.org/10.1136/jme-2023-109801
- Chamsi-Pasha H, Albar MA. Western and Islamic bioethics: How close is the gap? Avicenna J Med. 2013;3(1):8–14. https://doi.org/10.4103/2231-0770.112788